Catch my drift? Making sense of genomic intra-tumour heterogeneity.
MetadataShow full item record
The cancer genome is shaped by three components of the evolutionary process: mutation, selection and drift. While many studies have focused on the first two components, the role of drift in cancer evolution has received little attention. Drift occurs when all individuals in the population have the same likelihood of producing surviving offspring, and so by definition a drifting population is one that is evolving neutrally. Here we focus on how neutral evolution is manifested in the cancer genome. We discuss how neutral passenger mutations provide a magnifying glass that reveals the evolutionary dynamics underpinning cancer development, and outline how statistical inference can be used to quantify these dynamics from sequencing data. We argue that only after we understand the impact of neutral drift on the genome can we begin to make full sense of clonal selection. This article is part of a Special Issue entitled: Evolutionary principles - heterogeneity in cancer? Edited by Dr. Robert A. Gatenby.
Version of record
Clonal evolution of cancer
Next generation sequencing
Cell Transformation, Neoplastic
Gene Expression Regulation, Neoplastic
Genetic Predisposition to Disease
Evolutionary Genomics & Modelling
License start date
Biochim Biophys Acta, 1867 (2), pp. 95 - 100
Showing items related by title, author, creator and subject.
Liu, H; Liu, Z; Wang, Y; Stinchcombe, TE; Owzar, K; Han, Y; Hung, RJ; Brhane, Y; McLaughlin, J; Brennan, P; Bickeböller, H; Rosenberger, A; Houlston, RS; Caporaso, N; Landi, MT; Brüske, I; Risch, A; Wu, X; Ye, Y; Christiani, DC; Amos, CI; Wei, Q; Transdisciplinary Research in Cancer of the Lung (TRICL) Research Team (2017-05-01)Cullin-RING ubiquitin ligases (CRLs) responsible for substrate specificity of ubiquitination play a key role in cell-cycle control and DNA damage response. In this study, we assessed associations between 16 599 SNPs in 115 ...
Atlas of prostate cancer heritability in European and African-American men pinpoints tissue-specific regulation. Gusev, A; Shi, H; Kichaev, G; Pomerantz, M; Li, F; Long, HW; Ingles, SA; Kittles, RA; Strom, SS; Rybicki, BA; Nemesure, B; Isaacs, WB; Zheng, W; Pettaway, CA; Yeboah, ED; Tettey, Y; Biritwum, RB; Adjei, AA; Tay, E; Truelove, A; Niwa, S; Chokkalingam, AP; John, EM; Murphy, AB; Signorello, LB; Carpten, J; Leske, MC; Wu, SY; Hennis, AJ; Neslund-Dudas, C; Hsing, AW; Chu, L; Goodman, PJ; Klein, EA; Witte, JS; Casey, G; Kaggwa, S; Cook, MB; Stram, DO; Blot, WJ; Eeles, RA; Easton, D; Kote-Jarai, Z; Al Olama, AA; Benlloch, S; Muir, K; Giles, GG; Southey, MC; Fitzgerald, LM; Gronberg, H; Wiklund, F; Aly, M; Henderson, BE; Schleutker, J; Wahlfors, T; Tammela, TL; Nordestgaard, BG; Key, TJ; Travis, RC; Neal, DE; Donovan, JL; Hamdy, FC; Pharoah, P; Pashayan, N; Khaw, KT; Stanford, JL; Thibodeau, SN; McDonnell, SK; Schaid, DJ; Maier, C; Vogel, W; Luedeke, M; Herkommer, K; Kibel, AS; Cybulski, C; Wokolorczyk, D; Kluzniak, W; Cannon-Albright, L; Teerlink, C; Brenner, H; Dieffenbach, AK; Arndt, V; Park, JY; Sellers, TA; Lin, HY; Slavov, C; Kaneva, R; Mitev, V; Batra, J; Spurdle, A; Clements, JA; Teixeira, MR; Pandha, H; Michael, A; Paulo, P; Maia, S; Kierzek, A; Conti, DV; Albanes, D; Berg, C; Berndt, SI; Campa, D; Crawford, ED; Diver, WR; Gapstur, SM; Gaziano, JM; Giovannucci, E; Hoover, R; Hunter, DJ; Johansson, M; Kraft, P; Le Marchand, L; Lindström, S; Navarro, C; Overvad, K; Riboli, E; Siddiq, A; Stevens, VL; Trichopoulos, D; Vineis, P; Yeager, M; Trynka, G; Raychaudhuri, S; Schumacher, FR; Price, AL; Freedman, ML; Haiman, CA; Pasaniuc, B (2016-01)Although genome-wide association studies have identified over 100 risk loci that explain ∼33% of familial risk for prostate cancer (PrCa), their functional effects on risk remain largely unknown. Here we use genotype data ...
Vergote, I; Banerjee, S; Gerdes, A-M; van Asperen, C; Marth, C; Vaz, F; Ray-Coquard, I; Stoppa-Lyonnet, D; Gonzalez-Martin, A; Sehouli, J; Colombo, N (2016-12)Traditionally, BRCA genetic testing has been undertaken to identify patients and family members at future risk of developing cancer and patients have been referred for testing based on family history. However, the now ...